title: A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis.
authors.affiliation: Department of Surgery, Section of Otolaryngology-Head and Neck Surgery, The University of Chicago, Chicago, IL 60637, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Pinto
authors.forename: N
authors.initials: N
authors.lastname: Mehta
authors.forename: M
authors.initials: M
authors.lastname: DiTineo
authors.forename: J
authors.initials: J
authors.lastname: Wang
authors.forename: F M
authors.initials: FM
authors.lastname: Baroody
authors.forename: R M
authors.initials: RM
authors.lastname: Naclerio
mesh_terms: D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D006305:Health Status Indicators; D006801:Humans; D007073:Immunoglobulin E / Q000502:physiology; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D011788:Quality of Life; D012220:Rhinitis / Q000188:drug therapy* / Q000503:physiopathology; D012852:Sinusitis / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E